Hagens Berman Reminds Abiomed Investors Only Six Days Remain Before Jan. 15, 2013, Lead Plaintiff Deadline in Class-action

  Hagens Berman Reminds Abiomed Investors Only Six Days Remain Before Jan. 15,
  2013, Lead Plaintiff Deadline in Class-action Lawsuit

Business Wire

SEATTLE -- January 9, 2013

Hagens Berman Sobol Shapiro LLP, a securities law firm, today reminded
investors that only six days remain before the Jan. 15, 2013, deadline to seek
the position of lead plaintiff in a lawsuit filed on their behalf against
Abiomed, Inc. (NASDAQ:ABMD) (“Abiomed”).

Investors with losses greater than $100,000 who purchased or otherwise
acquired Abiomed stock between Aug. 5, 2011, and Oct. 31, 2012 (the “class
period”), may contact Hagens Berman to discuss moving for lead plaintiff in
the pending class-action lawsuit. Investors can contact Hagens Berman Partner
Reed R. Kathrein, who is leading the firm’s investigation, by calling
510-725-3000 or by emailing ABMD@Hbsslaw.com.

Any member of the proposed class may move the court to serve as lead plaintiff
through counsel of their choice, or may choose to do nothing and remain an
absent class member. Class members need not seek to become a lead plaintiff in
order to share in any possible recovery.

The lawsuit alleges that Abiomed misled investors regarding off-label
marketing of its flagship Impella system. Hagens Berman’s investigation
indicates that, contrary to FDA objections, Abiomed continued to promote
off-label use of the Impella until at least August 2012.

On Nov. 1, 2012, Abiomed disclosed that it was being investigated by the U.S.
Department of Justice regarding the marketing of Impella and had received a
HIPAA subpoena. Following the disclosure, Abiomed stock fell more than 30
percent.

Then on Dec. 6, 2012, the Food and Drug Administration’s 515 Program
Initiative Circulatory System Devices Panel met to discuss the issues
surrounding Abiomed and Impella. At the conclusion of the meeting the Advisory
voted to keep the Class III categorization of the Impella device. Accordingly,
Abiomed will be required to conduct PMA type trials.

More information about this investigation is available at
http://hb-securities.com/investigations/Abiomed.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm
with offices in 10 cities. The firm represents whistleblowers, workers and
consumers in complex litigation. More about the law firm and its successes can
be found at www.hbsslaw.com. The firm’s securities law blog is at
www.meaningfuldisclosure.com.

Contact:

Firmani + Associates
Mark Firmani, 206-443 9357
Mark@firmani.com
 
Press spacebar to pause and continue. Press esc to stop.